Built from Insmed Inc’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
$118.07-2.1%Nov 12 close
Figures through September 30, 2026, from the 10-Q filed October 29, 2026
Company outlook: revenue of $1.4B to $1.4B for Fiscal year 2026 — up 126.7% on a year earlier, slower than the 268.4% just reported
Just reported
From Insmed's results release of October 29, 2026; its quarterly report has since been filed.
Actual
$524.4M
+268% y/y
+23% q/q
Guided
—
No guide given
Actual
-$0.46
Guided
—
No guide given
Actual
-$89.4M
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Insmed is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade C-
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 36 quarters of Insmed Inc’s grade history. The other 34 go back to February 2018.
